비보스 테라퓨틱스VVOS 주가

Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts

Vivos Therapeutics Inc (VVOS) reports a 70% revenue increase, driven by strategic partnerships and a new business model, despite rising expenses and cash flow challenges.

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call May 20, 2026 5:00 PM EDTCompany ParticipantsBradford Amman - CFO, Treasurer & SecretaryR.

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Year-over-year revenue increased 70%, reflecting contribution from Vivos’ acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today

Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.45) by 15.56 percent. This is a 15.56 percent decrease over losses of $(0.45) per share

[10-Q] 분기 실적 — 10-Q

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

[NT 10-Q] 10-Q 제출 연기 — NT 10-Q

[SCHEDULE 13G] SCHEDULE 13G

[EFFECT] EFFECT

[424B3] 424B3 — 424B3